Published in Sci Rep on August 15, 2017
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
T1, T2 relaxation and magnetization transfer in tissue at 3T. Magn Reson Med (2005) 6.17
Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76
Biomedical photoacoustic imaging. Interface Focus (2011) 4.28
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Three-dimensional imaging of skin melanoma in vivo by dual-wavelength photoacoustic microscopy. J Biomed Opt (2006) 3.08
Quantitative spatially resolved measurement of tissue chromophore concentrations using photoacoustic spectroscopy: application to the measurement of blood oxygenation and haemoglobin concentration. Phys Med Biol (2006) 2.64
HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther (2002) 2.53
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther (2004) 2.16
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer (2006) 2.11
Detection of lipid in atherosclerotic vessels using ultrasound-guided spectroscopic intravascular photoacoustic imaging. Opt Express (2010) 1.84
Photoacoustic imaging in cancer detection, diagnosis, and treatment guidance. Trends Biotechnol (2011) 1.84
Melanin absorption spectroscopy: new method for noninvasive skin investigation and melanoma detection. J Biomed Opt (2008) 1.80
Fast semi-analytical model-based acoustic inversion for quantitative optoacoustic tomography. IEEE Trans Med Imaging (2010) 1.52
Tyrosinase as a dual reporter gene for both photoacoustic and magnetic resonance imaging. Biomed Opt Express (2011) 1.32
Emerging trends in the epidemiology of melanoma. Br J Dermatol (2014) 1.31
Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation. J Biol Chem (1996) 1.27
Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov (2014) 1.21
In vivo photoacoustic microscopy of human cutaneous microvasculature and a nevus. J Biomed Opt (2011) 1.20
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther (2008) 1.16
Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res (2015) 1.12
High-speed intravascular photoacoustic imaging of lipid-laden atherosclerotic plaque enabled by a 2-kHz barium nitrite raman laser. Sci Rep (2014) 1.09
Magnetic resonance in the era of molecular imaging of cancer. Magn Reson Imaging (2011) 1.08
BRAF inhibitors in cancer therapy. Pharmacol Ther (2013) 1.07
From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin Pharmacol Ther (2009) 1.06
Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging. Sci Transl Med (2015) 1.04
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Mol Cancer Ther (2014) 1.04
Paramagnetic agents for contrast-enhanced NMR imaging: a review. AJR Am J Roentgenol (1983) 1.03
Blind source unmixing in multi-spectral optoacoustic tomography. Opt Express (2011) 1.01
Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol (2016) 0.99
Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition. Oncotarget (2010) 0.98
Mapping lipid and collagen by multispectral photoacoustic imaging of chemical bond vibration. J Biomed Opt (2012) 0.95
Trametinib: first global approval. Drugs (2013) 0.95
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treat Rev (2015) 0.92
Statistical approach for optoacoustic image reconstruction in the presence of strong acoustic heterogeneities. IEEE Trans Med Imaging (2010) 0.92
Advances in targeted therapy for unresectable melanoma: new drugs and combinations. Cancer Lett (2015) 0.91
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol (2016) 0.87
Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. Br J Cancer (2013) 0.86
In vivo photoacoustic tomography of myoglobin oxygen saturation. J Biomed Opt (2016) 0.86
Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review). Int J Oncol (2014) 0.85
Dabrafenib: first global approval. Drugs (2013) 0.85
Multi-wavelength photoacoustic imaging of inducible tyrosinase reporter gene expression in xenograft tumors. Sci Rep (2014) 0.85
Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. PLoS One (2014) 0.82
Malignant melanoma: relationship to parameters of differentiation. Melanoma Res (1992) 0.81
Critical parameters in targeted drug development: the pharmacological audit trail. Semin Oncol (2016) 0.80
Estimation of optoacoustic contrast agent concentration with self-calibration blind logarithmic unmixing. Phys Med Biol (2014) 0.78
TYR as a multifunctional reporter gene regulated by the Tet-on system for multimodality imaging: an in vitro study. Sci Rep (2015) 0.75
The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox. J Invest Dermatol (2015) 0.75
Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells. PLoS One (2014) 0.75
Photoacoustic imaging features of intraocular tumors: Retinoblastoma and uveal melanoma. PLoS One (2017) 0.75